Stealth nanoparticles coated with heparin as peptide or protein carriers

Abstract

Nanoparticles (prepared from a mixture of polyester and a polycationic polymer) loaded with insulin were prepared by a double emulsion method followed by evaporation solvent. Low molecular weight heparin (LMWH) was bound by electrostatic interactions onto the surface of the particles to confer Stealth properties. These nanoparticles were characterized in vitro (mean diameter, zeta potential, encapsulation efficiency, and release kinetics) and compared with conventional (without LMWH) and unloaded nanoparticles. The pharmacokinetics of insulin were studied after intravenous injection into diabetic rats in the form of Stealth or conventional nanoparticles or as a solution. Stealth nanoparticles allowed an increase in the elimination half-life of insulin, showing that the hydrophilic layer of LMWH was able to limit recognition by the mononuclear phagocytosis system in vivo. However, complement activation studies (CH50) did not reveal significant difference between Stealth and conventional nanoparticles.

Heparin‐Engineered Mesoporous Iron Metal‐Organic Framework Nanoparticles: Toward Stealth Drug Nanocarriers

“…Although the heparin coating approach has been previously reported for preventing from the rapid macrophage uptake for different classes of NPs, [33][34][35][36] to the best of our knowledge, this is the fi rst time that the surface heparin-engineering of MOFs is reported, providing them with remarkable potential stealth properties.…”

“…[ 31 ] Consequently, longer blood circulation times are expected in order to modify their in vivo fate. [32][33][34][35][36] Finally, we describe here a new method to coat the outer surface of porous nanoMOFs through a biofriendly one-pot method that ensures the preservation of the physicochemical features of the porous NPs.…”

Preparation of multifunctional polymeric micelles for antiviral treatment

“…PLLA-b-PEG-mNA micelles possessing negative electrical charges were expected to be more stable in the blood stream than that of PLLA-b-mPEG. 25,26 In addition, the electrostatic repulsion effect of the mNA block for negative charged blood proteins, such as bovine serum albumin (BSA), and the antifouling activity of PEG 17,18 may act in synergy to significantly prevent aggregation of PLLA-b-PEG-mNA micelles in blood. Figure 5 shows the in vitro binding ability of PLLA-b-PEG-mNA micelles on hemagglutinin protein derived from influenza virus.…”

Heparin‐Based Nanocapsules as Potential Drug Delivery Systems

“…[5] Socha et al studied the release of insulin-loaded particles with a heparin-coated surface, characterized these particles in vitro (diameter, zeta potential, encapsulation efficiency, and release kinetics) and studied the pharmacokinetics after intravenous injection. [6] They found an increase in the elimination half-life of insulin showing a limitation in recognition by the mononuclear phagocytosis system in vivo. Passirani et al compared nanoparticles bearing heparin or dextran covalently bound to the surface.…”